A double-blind, randomized study to compare the efficacy and safety of terbinafine (Lamisil®) with fluconazole (Diflucan®) in the treatment of onychomycosis

Abstract

In a randomized, double-blind, double-placebo, multicentre study, terbinafine 250 mg daily for 12 weeks was compared with fluconazole 150 mg once weekly for 12 or 24 weeks in the treatment of onychomycosis. A total of 137 patients with culture-confirmed onychomycosis was divided into three groups: group A received terbinafine for 12 weeks, group B received fluconazole for 12 weeks, while group C received fluconazole for 24 weeks. At completion of the study (week 60), the mycological cure rate was higher in the terbinafine group than in the fluconazole groups: 89% vs. 51% and 49%, respectively (P < 0.001). The length of unaffected nail increased until week 24 in group B and until week 36 in group C, but was still increasing in group A at the final visit (week 60). Complete clinical cure of the target nail at week 60 was 67% in the terbinafine group, compared with 21% and 32% in the fluconazole groups, respectively. The incidence of adverse events was low for both study agents. We conclude that terbinafine 250 mg daily for 12 weeks is significantly more effective in the treatment of onychomycosis than fluconazole 150 mg once weekly for either 12 or 24 weeks.

Chronic Mycotic-Associated Surgical Nail Pathology Complicated With Ingrown Nail (Nail Incarnation): The Analyses of Clinical Cases and Complex Treatment

“…Investigation of the morphogenesis of destructive aspect of the mycotic lesions was carried out. A variety of factors, aetiology, and pathogenesis of chronic purulent necrotic lesions of the foot, contributing to the occurrence, progression and recurrent course of these diseases, creates objective difficulties of diagnosis [14,16,19]. the analysis justifies the feasibility of establishing predictive relationships between clinical variants of chronic purulent necrotic infections and combined comorbidity [1,25].…”

Mycosis-Induced Nail Ingrowth in Patients With Diabetes Mellitus and Metabolic Syndrome: Approaches to the Problem

“…Також у післяопераційному періоді за показаннями призначали системну пульс-терапію ітраконазолом у кількості 2-3 стандарт-них д'ятиденних циклів. Після епітелізації ран застосовували лінімент тер-бінафіну до повного відростання нігтів [1,6]. Показники ліпідного спектру крові (ЗХС, ХС ЛПНЩ) були істотно ви-щими в обох групах пацієнтів (основної та групі порівняння), р<0,01 для обох груп, порівняно з контролем, що відповідає даним літератури.…”

Onychomycosis - a kórokozók fajspektruma és terápia

“…Lábkörmök fertôzöttsége esetén 3, kéz-körmök fertôzöttsége esetén 2 lökés ajánlott. Az onychomycosis kezeléséhez a fluconazole terápia (150-300 mg/hét) is hozzátartozik, amit a teljes gyógyulás eléré-séig, azaz a körmök lenövéséig kell alkalmazni, de eredményessége nem közelíti meg a terbinafine-ét (25,26 …”